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1 Drug description 
Generic/Brand name/ATC code:  
Bortezomib (formerly known as PS-341) / Velcade® / L01XX32 
Developer/Company:  
USA: Millenium Pharmaceuticals; Europe: Janssen-Cilag International NV 
Description:  
The antineoplastic agent bortezomib is a first-in-class proteasome inhibitor 
[1]. Particularly, bortezomib is a dipeptide boronic acid analogue whose 
anti-tumour activity leads to cell cycle arrest, apoptosis and inhibition of 
angiogenesis by disrupting various cell signalling pathways [2].  
Velcade® is currently approved as an intravenous (i.v.) infusion of 1.3mg per 
square meter body surface area. Bortezomib is approved as monotherapy in 
progressive MM and in combination with other agents as first-line therapy 
in transplant ineligible patients. When given together with melphalan and 
prednisone, bortezomib is given twice weekly on weeks 1, 2, 4 and 5 of a six-
week cycle. This cycle is given 4 times followed by 5 weeks of once-weekly 
injections. When bortezomib is given as a single-agent, it is recommended 
twice weekly in weeks 1 and 2 of a three weeks cycle. Complete responders 
should receive 3 cycles; partial responders should receive up to eight treat-
ment cycles [3]. 
Currently, the mode of administration – subcutaneous (s.c.) vs. i.v. – is in-
vestigated in clinical trials. The objective is to establish if s.c. administration 
maintains efficacy while simultaneously improving the safety profile, fore-
most in terms of a lower incidence of peripheral neuropathy, an adverse 
event (AE) caused by bortezomib and impairing the quality of life of multi-
ple myeloma (MM) patients [4]. 
2 Indication 
Bortezomib as consolidation or maintenance therapy after high-dose therapy 
(HDT) with autologous stem-cell transplantation (ASCT) in patients with 
newly diagnosed multiple myeloma. 
bortezomib (Velcade®) 
a proteasome inhibitor 
leading to cell cycle 
arrest, apoptosis and in-
hibition of angiogenesis 
approved at a dose of 
1.3mg/m2 i.v. infusion 
i.v. vs. s.c. 
administration 
bortezomib as 
consolidation or 
maintenance therapy 
after ASCT 
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3 Current regulatory status 
In Europe, Velcade® is approved  
 as monotherapy for the treatment of patients with progressive MM 
who have received at least 1 prior therapy and who have already un-
dergone or are unsuitable for bone marrow transplantation (since 
April 2004), 
 and in combination with melphalan and prednisone for the treatment 
of patients with previously untreated MM who are not eligible for 
high-dose chemotherapy with bone marrow transplant (since Septem-
ber 2008) [3, 5]. 
In May 2003, the US Food and Drug Administration (FDA) approved borte-
zomib (Velcade®)  
 for the treatment of MM patients who have received at least two prior 
therapies and have demonstrated disease progression on the last ther-
apy [6]; this indication was later on revised to failure of at least one 
prior therapy in 2005 [7] and then to treatment of patients with MM 
regardless of prior therapy in 2008 [8]. 
 In 2006, the indication of bortezomib was extended to patients with 
mantle cell lymphoma who have received at least one prior therapy 
[9]. 
4 Burden of disease 
MM is a malignant neoplasm of plasma cells that belongs to the type of B-
cell lymphoma. MM accounts for about 10% of all haematological malignan-
cies and is after non-Hodgkin’s lymphoma (NHL) the second most common 
hematologic malignancy [10, 11]. The incidence of MM is estimated to be 4-
6 per 100,000 habitants with a median age of 70 years at time of diagnosis 
and men being more often affected than women. About 20% of patients are 
symptom-free at time of diagnosis [12, 13]. MM is often referred to as a dis-
ease of the elderly with only about 35% of MM patients being younger than 
65 years [4, 14]. Raised erythrocyte sedimentation rate (ESR), plasma viscos-
ity, serum protein or globulin lead to incidental detection of MM. Clinical 
features of MM present at time of diagnosis are bone disease, impaired renal 
function, anaemia, hypercalcaemia, recurrent or persistent bacterial infec-
tion and hyperviscosity [15]. 
If MM is suspected, a range of investigations and tests are indicated to con-
firm diagnosis, estimate tumour burden and prognosis and to assess mye-
loma-related organ impairment. Further, these tests aim to differentiate be-
tween patients with active and symptomatic MM that requires systemic 
therapy and monoclonal gammopathy of undetermined significance 
(MGUS), smouldering or indolent lymphoma or solitary plasmocytoma, all 
of which not requiring systemic therapy in the first instance [10, 13, 15].  
in Europe approved for 
the treatment of 
transplant-ineligible 
MM patients 
2008: approval for the 
treatment of MM 
patients 
 
 
2006: approved for the 
treatment of mantle cell 
lymphoma 
MM accounts for ˜10% 
of haematologic 
malignancies  
 
incidence: 4-6 per 
100,000 habitants 
median age at diagnosis: 
70 years (35% of MM 
patients are <65 years) 
tests to confirm 
diagnosis, estimate 
tumour burden and 
prognosis 
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The natural history of MM is very heterogeneous. Initially, the Durie and 
Salmon system [16] was the staging system of choice until it was superseded 
by the International Staging System (ISS) for MM [17]. The ISS defines 3 
risk categories (stages I, II and III) with a corresponding median survival 
time of 62, 45 and 29 months in stages I, II and III, respectively. Especially 
biological parameters (e.g., β2-microglobulin, C-reactive protein, lactate de-
hydrogenase and serum albumin) are of prognostic relevance and thus in-
corporated in the determination of the ISS stages [13, 15]. Though, the ISS 
is valid for prognostic purposes, its use to determine choice of therapy for 
individual patients is still unproven [15]. Factors associated with poor prog-
nosis are genetic abnormalities such as t(4;14), t(14;16) and deletion 17p 
(del(17p)) demonstrated by fluorescence in situ hybridisation (FISH) [15]. 
Patients presenting these prognostic factors are generally referred to as 
“high-risk” MM patients. Preliminary data suggest that the adverse progno-
sis of these factors may be abrogated by newer agents, but to confirm this ob-
servation further prospective evaluation is required [15].  
According to clinical treatment guidelines only patients younger than 65 
years are eligible for ASCT. With an incidence of 4 per 100,000 habitants 
[12, 13], there are about 360 patients newly diagnosed with MM in Austria 
per year. Applying the above mentioned estimates, there are about 100 pa-
tients younger than 65 years diagnosed with symptomatic disease and thus, 
eligible for first-line therapy with ASCT. In 2011, there were 120 MM trans-
plantations overall in Austria. These 120 transplantations were 6 allogeneic 
SCTs, 99 first-line ASCTs and 15 second- or third-line transplantations [18]. 
5 Current treatment 
In the first instance, choice of therapy depends on the stage of disease and 
on presence or absence of symptoms. For MM of ISS stage I or indolent mye-
loma immediate treatment is not recommended [13].  
For patients with advanced stages (stage II or III) or symptomatic myeloma 
choice of first-line therapy depends on age, or at least on the overall condi-
tion of the MM patient. For younger patients (<65 years) or patients in good 
clinical condition the current standard of care is high-dose therapy (HDT) 
with melphalan (HDM) supported by ASCT. The arbitrary age limit of 65 
years is not a strict limit; the decision whether MM patients are eligible for 
HDT with ASCT mainly depends on their overall performance status and 
co-morbidities (e.g. serious heart, lung, renal or liver dysfunction) [19, 20]. 
In clinical practice the age limit for ASCT is between 65 to 70 years. 
Prior to HDT and ASCT, eligible patients receive a limited number (3-6 cy-
cles) of induction therapy in order to reduce tumour cell mass and bone 
marrow plasma cell infiltration before the collection of peripheral blood 
stem cells [4, 15]. Prior to the introduction of novel agents such as thalido-
mide, lenalidomide and bortezomib, the standard induction regimen was 
VAD (vincristine, doxorubicin and dexamethasone) yielding overall re-
sponse rates of 55% to 84% and complete response rates (CR) of 8% to 28% 
[15]. In recent years, however, novel agents have been incorporated in dou-
blet and triplet induction regimens in order to enhance the depth of re-
heterogeneous natural 
history 
3 risk categories 
according to ISS: stage I, 
II and III 
 
 
factors for poor 
prognosis: genetic 
abnormalities = high-
risk patients 
100 newly diagnosed 
patients <65 years with 
symptomatic MM in 
Austria per year 
watch-and-wait for 
asymptomatic MM 
symptomatic MM: 
1st-line therapy is HDT 
with ASCT support in 
patients <65 years 
1st-line therapy for 
patients eligible for HDT 
supported by ASCT 
this approach is 
currently discussed 
because of the 
availability and 
promising results of 
novel agents 
Horizon Scanning in Oncology 
6 LBI-HTA | 2012 
sponse prior and post ASCT [4]. Due to promising results no commonly ac-
cepted standard induction regimen currently exists. 
Another issue is that these novel agents are not yet approved in all countries 
(e.g. bortezomib in Europe [5]); therefore, the choice of induction therapy 
also depends on the availability of these novel drugs in the individual health 
care systems [4]. 
 
CONSOLIDATION and MAINTENANCE THERAPY 
The rationale behind administration of consolidation and maintenance 
therapy is to improve responses after HDT with ASCT. Whereas consolida-
tion therapy is given for a short period immediately after ASCT aiming at 
improving responses to HDT, maintenance therapy is given for a longer pe-
riod and aims to extend the duration of response, progression-free survival 
(PFS) and overall survival (OS) while maintaining a good quality of life [4].  
Though, the treatment paradigm of the introduction of novel agents as con-
solidation and maintenance therapy is currently investigated in clinical tri-
als, mature results demonstrating the positive impact, of consolidation and 
maintenance therapy on clinical outcomes are needed before the widespread 
introduction into clinical practice [4]. 
Currently, the following regimens are used as consolidation and mainte-
nance therapy:  
 thalidomide as single agent or in combination with prednisone, 
 lenalidomide would be an alternative to thalidomide because of re-
duced neurologic toxicity [4]. 
 
Allogeneic stem-cell transplantation (alloSCT) is also considered to be an 
option for the treatment of MM and is currently the only treatment ap-
proach achieving complete remission or even cure. Though, alloSCT is not 
recommended for standard-risk patients due to a transplant-related mortal-
ity of 10-15% and the risk of chronic graft-versus-host disease (GVHD). Al-
loSCT should only be performed in high-risk patients within clinical trials 
[13].  
6 Evidence 
A literature search was conducted on the 24th of May 2012 in 4 databases 
(Ovid Medline, Embase, Cochrane Library, CRD Database) yielding 262 re-
sults. Considered were controlled phase III and phase II studies investigat-
ing the effect of the novel agent bortezomib in the consolidation or mainte-
nance setting after ASCT in newly diagnosed MM patients. 
Overall, 2 references [20, 21] reporting results of 2 phase III studies – one as-
sessing bortezomib as consolidation therapy and one assessing bortezomib as 
maintenance therapy – were included. In mid of July 2012, during compila-
tion of this report results of the HOVON-65/GMMG-HD4 trial were pub-
lished by Sonneveld et al [22] and thus included in this report. Though, sev-
eral phase II studies investigating bortezomib as consolidation or mainte-
induction with novel 
agents: not all are 
approved as induction 
treatment yet 
role of consolidation 
and maintenance 
therapy still has to be 
defined 
alloSCT not 
recommended in 
standard-risk patients 
search in 4 databases 
yielding 262 references 
2 controlled phase III 
studies included 
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nance therapy were identified in the search, these trials were not included 
herein as they had no control group. 
6.1 Efficacy and safety - Phase III studies 
6.1.1 Consolidation therapy 
 
Table 1: Summary of efficacy results of the NCT01134484 trial 
Study title  
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone 
as induction therapy before, and consolidation therapy after, double autologous stem-cell transplan-
tation in newly diagnosed multiple myeloma: a randomised phase 3 study [20] 
Study identifier ClinicalTrials.gov: NCT01134484 
EudraCT: 2005-003723-39 
open-label, multicentre, randomised phase III trial Design 
Duration  Enrolment: May 2006 – April 2008 
Median follow-up: 36 months, but study still on-going at time of 
report publication, but not recruiting patients 
Cut-off date for the available report: June 30, 2010 
Hypothesis Superiority 
Funding Sera`gnoli Institute of Haematology at the University of Bologna: coordinated study, 
contributed to study design, data collection, data analysis, data interpretation, writing 
of the report, and the decision to submit for publication 
Janssen-Cilag: provided bortezomib free of charge 
Treatment 
groups 
Intervention 
1. INDUCTION THERAPY 
three 21-day cycles of bortezomib, thalidomide and dexamethasone 
(VTD)  1.3mg/m2 bortezomib on days 1, 4, 8 and 11  100mg thalidomide daily for the first 14 days and 200mg daily 
thereafter  40mg dexamethasone daily on 8 of the first 12 days but not con-
secutively; total of 320mg per cycle 
2. ASCT 
 mobilization of peripheral blood stem cells: 4g/m2 cyclophos-
phamide; 10μg/kg G-CSF daily starting on day 2 after cyclophos-
phamide  double ASCT – 3-6 months apart from each other  both transplantations were supported by 200mg/m2 melphalan; 
5μg/kg G-CSF daily starting on day 5 after melphalan  between the transplantations 100mg thalidomide daily and 40mg 
dexamethasone on days 1-4, every 28 days were given 
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3. CONSOLIDATION THERAPY (3 months after ASCT) 
two 35-day cycles of VTD therapy 
 1.3mg/m2 bortezomib on days 1, 8, 15 and 22  100mg thalidomide daily  40mg dexamethasone on days 1, 2, 8, 9, 15, 16, 22 and 23 
4. MAINTENANCE THERAPY 
 40mg dexamethasone on days 1-4 every 28 days 
Control 
1. INDUCTION THERAPY 
three 21-day cycles of thalidomide and dexamthasone (TD)  100mg thalidomide daily for the first 14 days and 200mg daily 
thereafter) 
 40mg dexamethasone daily on 8 of the first 12 days but not con-
secutively; total of 320mg per cycle) 
2. ASCT 
 mobilization of peripheral blood stem cells: 4g/m2 cyclophos-
phamide; 10μg/kg G-CSF daily starting on day 2 after cyclophos-
phamide 
 double ASCT – 3-6 months apart from each other  both transplantations were supported by 200mg/m2 melphalan; 
5μg/kg G-CSF daily starting on day 5 after melphalan 
 between the transplantations 100mg thalidomide daily and 40mg 
dexamethasone on days 1-4, every 28 days were given 
3. CONSOLIDATION THERAPY (3 months after ASCT) 
two 35-day cycles of TD therapy  100mg thalidomide daily  40mg dexamethasone on days 1-4 and 20-23 
4. MAINTENANCE THERAPY 
 40mg dexamethasone on days 1-4 every 28 days 
Rate of complete or 
near complete re-
sponse to induction 
therapy 
(primary outcome) 
CR / 
nCR 
complete response [23]:  
- negative immunofixation on the serum and urine 
- disappearance of any soft tissue plasmacytomas 
- ≤5% plasma cells in bone marrow 
- no increase in tumour size of lytic bone lesions 
 
near complete response [24]:  
- absence of myeloma protein on electrophoresis, in-
dependent of the immunofixation-test status 
- stable bone disease 
- normal serum calcium concentration 
Time to best CR or 
nCR 
 time from start of treatment to complete or near com-
plete response achieved at any time 
Time to progression  TTP time from start of treatment to progression 
Time to relapse TTR time from start of treatment to relapse 
Progression-free 
survival 
PFS time form start of treatment to progression, or death 
from any cause 
Overall survival OS time from start of treatment to death 
Endpoints and 
definitions 
Very good partial 
response 
VGPR serum and urine M-protein detectable by immunofixation 
but not on electrophoresis or 90% or greater reduction in 
serum M-protein plus urine M-protein <100mg per 24h 
[25] 
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Partial response PR - ≥50% reduction in the level of the serum mono-
clonal paraprotein, maintained for a minimum of 6 
weeks 
- reduction in 24h urinary light chain excretion either 
by ≥90% or to <200mg, maintained for a minimum 
of 6 weeks 
- for patients with non-secretory myeloma only, 
≥50% reduction in plasma cells in a bone marrow 
aspirate and on trephine biopsy, if biopsy is per-
formed, maintained for a minimum of 6 weeks 
- ≥50% reduction in the size of soft tissue plasmacy-
tomas (by radiography or clinical examination) 
- no increase in size or number of lytic bone lesions 
(development of a compression fracture does not 
exclude response) 
Minimal response 
or Stable disease 
MR / 
SD 
minimal response [23] 
- 25-49% reduction in the level of serum monoclonal 
paraprotein 
- 50-89% reduction in 24h urinary light chain excre-
tion 
- for patients with non-secretory MM only, 25-49% 
reduction in plasma cells 
- 25-49% reduction in the size of soft tissue plas-
macytomas 
- no increase in the size or number of lytic bone le-
sions 
 
stable disease [23] 
- not meeting the criteria of either minimal response 
or progressive disease 
Progressive disease PD - >25% increase of the level of serum monoclonal 
paraprotein 
- >25% increase in 24h urinary light chain excretion 
- >25% increase in plasma cells 
- definite increase in the size of existing bone lesions 
or soft tissue plasmacytoma 
- development of new bone lesions or soft tissue 
plasmacytoma 
- development of hypercalcaemia not attributable to 
any other cause 
Results and analysis 
Analysis 
description 
intention-to-treat analysis 
80% power to detect a significant increase in rate of complete plus near complete re-
sponse from 15% with TD induction therapy to 27% with VTD induction therapy. All 
tests were two-sided with p values of less than 0.05 deemed significant 
Analysis popula-
tion 
Inclusion  18-65 years of age  previously untreated symptomatic and measurable myeloma  Karnofsky performance status of ≥60%  adequate haematological function 
- absolute neutrophil count of ≥1.0x109 per litre 
- platelet count of ≥70x109 per litre  adequate renal function  
- serum creatinine of ≤176 μmol/litre 
 adequate cardiac function = absence of  
- uncontrolled or severe cardiovascular disease including myocar-
dial infarction within 6 months of enrolment 
Horizon Scanning in Oncology 
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- New York Heart Association class II-IV heart failure 
- uncontrolled angina 
- clinically significant pericardial disease 
- cardiac amyloidosis  adequate hepatic function 
- aspartate aminotransferase ≤2.5 times the upper limit of nor-
mal (ULN) 
- total bilirubin ≤1.5 times the ULN 
Exclusion  peripheral neuropathy of grade ≥2 according to National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE, version 3.0) 
 history of venous thromboembolism  previous diagnosis of thrombophylic alterations 
 Characteristics Intervention vs Control, % 
Median age, years (range): 58 (52 to 62) vs 57 (51 to 62) 
Male/female: 58/42 vs 57/43 
Myeloma subtype 
IgG/IgA/Light Chain: 65/17/17 vs 62/23/14 
ISS stage I/II/III: 45/39/16 vs 45/39/16 
FISH analysis for cytogenetic abnormalities 
absence of del(13q), t(4;14), or del(17p): 46 vs 48 
presence of del(13q): 47 vs 46 
presence of t(4;14) with or without del(17p): 24 vs 26 
Treatment group Intervention (VDT)  Control (TD) 
Number of subjects n = 236 n = 238 
P value 
After induction therapy, n (%; 95% CI) 
CR 
CR or nCR 
VGPR or better 
PR or better 
Minimal response or SD 
PD 
44 (19; 13.7 to 23.6) 
73 (31; 25.0 to 36.8) 
146 (62; 55.7 to 68.1) 
220 (93; 90.0 to 96.4)
16 (7; 3.6 to 10.0) 
0 
11 (5; 2.0 to 7.3) 
27 (11; 7.3 to 15.4) 
66 (28; 22.0 to 33.4) 
187 (79; 73.4 to 83.8) 
39 (16; 11.7 to 21.1) 
12 (5; 2.3 to 7.8) 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.0011 
0.0005 
After first ASCT 
CR 
CR or nCR 
VGPR or better 
PR or better 
Minimal response or SD 
PD 
89 (38; 31.5 to 43.9) 
123 (52; 45.7 to 58.5) 
186 (79; 73.6 to 84.0) 
220 (93; 90.0 to 96.4)
15 (6; 3.2 to 9.5) 
1 (<1; 0.0 to 1.3) 
54 (23; 17.4 to 28.0) 
74 (31; 25.2 to 37.0) 
137 (58; 51.3 to 63.8) 
201 (84; 79.9 to 89.1) 
20 (8; 4.9 to 11.9) 
17 (7; 3.9 to 10.4) 
0.0004 
<0.0001 
<0.0001 
0.0025 
0.39 
0.0001 
After second ASCT 
Descriptive sta-
tistics and esti-
mated variabil-
ity 
CR 
CR or nCR 
VGPR or better 
PR or better 
Minimal response or SD 
PD 
98 (42; 35.2 to 47.8) 
130 (55; 48.7 to 61.4) 
193 (82; 76.9 to 86.7) 
220 (93; 90.0 to 96.4)
14 (6; 2.9 to 8.9) 
2 (1; 0.0 to 2.0) 
72 (30; 24.4 to 36.1) 
98 (41; 34.9 to 47.4) 
152 (64; 57.8 to 70.0) 
199 (84; 78.9 to 88.3) 
19 (8; 4.5 to 11.9) 
20 (8; 4.9 to 11.9) 
0.0105 
0.0024 
<0.0001 
0.0011 
0.38 
0.0001 
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After consolidation therapy 
CR 
CR or nCR 
VGPR or better 
PR or better 
Minimal response or SD 
PD 
116 (49; 42.8 to 55.5) 
147 (62; 56.1 to 68.5) 
201 (85; 80.6 to 89.7) 
218 (92; 89.0 to 95.8) 
12 (5; 2.3 to 7.9) 
6 (3; 0.5 to 4.6) 
82 (34; 28.4 to 40.5) 
108 (45; 39.1 to 51.7) 
162 (68; 62.1 to 74.0) 
201 (84; 79.9 to 89.1) 
16 (7; 3.5 to 9.9) 
21 (9; 5.2 to 12.4) 
0.0012 
0.0002 
<0.0001 
0.0071 
0.45 
0.0032 
Best response to overall treatment protocol 
CR 
CR or nCR 
VGPR or better 
PR or better 
Minimal response, SD or 
PD 
136 (58; 51.3 to 63.9) 
168 (71; 65.4 to 77.0) 
210 (89; 85.0 to 93.0) 
227 (96; 93.7 to 98.6) 
9 (4; 1.4 to 6.3) 
97 (41; 34.5 to 47.0) 
128 (54; 47.4 to 60.1) 
175 (74; 67.9 to 79.1) 
212 (89; 85.1 to 93.0) 
26 (11; 7.0 to 14.9) 
0.0001 
<0.0001 
<0.0001 
0.0031 
0.0031 
Median time to CR or 
nCR, months (interquar-
tile range) 
9 (3.1 to NR) 14 (8.4 to NR) <0.0001 
Estimated 3-year prob-
ability of progression or 
relapse 
29% 39% 0.0061 
Estimated 3-year PFS 68% 56% 0.0057 
Estimated 3-year OS 86% 84% 0.30 
Comparison groups Intervention (VDT) vs Control (TD) 
HR 0.61 
95% CI 0.49 to 0.76 
Median time to CR or 
nCR 
P value  <0.0001 
HR 0.61 
95% CI 0.43 to 0.87 
Estimated 3-year prob-
ability of progression or 
relapse 
P value  0.0073 
HR 0.63 
95% CI 0.45 to 0.88 
Effect estimate 
per comparison 
PFS 
P value  0.0061 
Abbreviations: NR – not reached, CI – confidence interval, HR – hazard ratio 
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Table 2: Most frequent adverse events according to NCI-CTCAE version 3.0 
 NCT01134484 
 Outcome, n (%) Intervention (VTD) 
(n=236) 
Control (TD) 
(n=238) P value 
Grade 1 – 4 non-haematological AEs 
reported in at least 10% of patients during induction therapy 
Constipation 99 (42) 67 (28) NR 
Neuropathy 80 (34) 34 (14) NR 
Skin rash 67 (28) 17 (7) NR 
Fever 28 (12) 24 (10) NR 
Infections 24 (10) 35 (15) NR 
Oedema 25 (11) 13 (5) NR 
 
Gastrointestinal events (ex-
cluding constipation) 
46 (19) 19 (8) NR 
Serious AEs and grade 3 or 4 AEs 
reported in at least 2% of patients during induction therapy 
Any serious AE 31 (13) 30 (13) 0.86 
Any grade 3 or 4 AE 132 (56) 79 (33) <0.0001 
Any grade 3 or 4 non-
haematological AE 
120 (51) 73 (31) <0.0001 
Skin rash 24 (10) 4 (2) 0.0001 
Peripheral neuropathy 23 (10) 5 (2) 0.0004 
Deep vein thrombosis 8 (3) 12 (5) 0.53 
Constipation 10 (4) 7 (3) 0.45 
Infections excluding herpes 
zoster 
7 (3) 11 (5) 0.35 
Gastrointestinal events (ex-
cluding constipation) 
5 (2) 1 (<1) 0.0982 
Cardiac toxicity 5 (2) 5 (2) 0.99 
 
Liver toxicity 4 (2) 7 (3) 0.37 
Discontinuation during or after induction therapy 
Overall 13 (6) 26 (11) 0.0319 
Toxic effects 10 (4) 7 (3) 0.45 
Disease progression 0 12 (5) <0.0001 
Other reasons 2 (1) 7 (3) 0.21 
 
Early death 1 (<1) 0 0.31 
Discontinuation during or after consolidation therapy 
Toxic effects 4 1 NR 
Disease progression 4 1 NR 
 
Other reason 4 3 NR 
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474 patients (I 236 vs C 238) with previously untreated myeloma received 
thalidomide and dexamethasone with or without bortezomib as induction 
therapy and also as consolidation therapy after ASCT. The primary end-
point was CR and nCR to induction therapy. Thus, drawing definite conclu-
sions on bortezomib consolidation therapy is difficult since the study was 
powered to detect an increase in rate of CR plus nCR after induction ther-
apy with VTD compared to TD. Secondary endpoints were CR or nCR to 
double transplantation and subsequent consolidation therapy with the in-
duction regimen. The baseline patient and disease characteristics were well 
balanced. Cytogenetic abnormalities such as del(13q) and t(4;14) were pre-
sent in 46-47% and 24-26% of patients, respectively.  
Throughout the study (induction therapy, high-dose therapy + ASCT and 
consolidation therapy) clinical outcomes (CR, nCR, VGPR, PR) were better 
in the intervention arm than in the control arm: 58% of patients in the in-
tervention arm achieved CR as a best response compared to 41% in the con-
trol arm. To which extent the superior response rate after consolidation 
therapy is actually attributable to consolidation therapy with bortezomib is 
unknown due to lack of random allocation to consolidation therapy and also 
the response upgrade (i.e. <CR prior consolidation and then achieving CR 
during / after consolidation therapy), if any, during consolidation therapy 
was not reported.  
Median PFS was superior for patients treated with VTD (HR 0.63, 
p=0.0061) and median time to CR or nCR was 5 months (p<0.0001) shorter 
in this group. Data on cytogenetic abnormalities associated with poor prog-
nosis were available from 90% of patients. Subgroup analyses according to 
the cytogenetic abnormalities indicated that VTD as induction and consoli-
dation therapy can overcome the adverse effect of t(4;14) compared to TD 
alone. 
Reported AEs were those observed after induction therapy. Information 
about AEs during or after bortezomib consolidation is lacking. The two most 
common grade 3 and 4 AEs were peripheral neuropathy and skin rash, both 
occurring more frequently in the VTD than in the TD arm. The only AE re-
ported in the publication during consolidation therapy was frequency of pe-
ripheral neuropathy which affected 2 patients (1%) in the VTD arm and 
none in the TD arm. 
Of the 236 patients in the VTD arm 227 completed induction therapy, 212 
and 168 completed one or two transplantations, respectively and 165 com-
pleted 2 cycles of VTD consolidation therapy. In the TD arm 238 patients 
received induction therapy, 196 and 166 completed one or two transplanta-
tions, respectively and 165 completed two cycles of TD consolidation ther-
apy. 
 
bortezomib as induction 
therapy before and 
consolidation therapy 
after ASCT 
improved response rate 
with bortezomib 
throughout the study 
I 58% vs C 41% 
effect of bortezomib as 
consolidation therapy 
still unknown 
results suggest that 
bortezomib can 
overcome the adverse 
prognosis of t(4;14) 
most common and most 
severe AEs: 
peripheral neuropathy, 
skin rash 
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6.1.2 Maintenance therapy 
Table 3: Summary of efficacy results of the HOVON-65/GMMG-HD4 trial 
Study title  
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Re-
sults of the randomized phase III HOVON-65/GMMG-HD4 trial [22]. 
Study identifier International Standard Randomised Controlled Trial Number Register: IS-RCTN64455289 
EudtraCT Number: 2004-000944-26 
Prospective, randomized phase III trial (HOVON-65/GMMG-HD4); 75 centres in the Netherlands, 
Germany and Belgium. 
Design 
Duration  Enrolment: May 2005 –May 2008 
Median follow-up: 40.9 months (95% CI, 39.7 to 42.5) 
Cut-off date for final analysis: NR 
Hypothesis Superiority 
Funding Supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Re-
search, and unrestricted Grant No. MMY3003 from Janssen-Cilag-Ortho Biotech. The German 
Multicenter Myeloma Group was supported by grants from Novartis, Amgen (No. P2004-0060), 
Chugai and Roche. 
Intervention 
1. INDUCTION THERAPY 
three 4-week cycles of bortezomib, doxorubicin and dexamethasone (PAD) 
 bortezomib: 1.3mg/m2 i.v. on days 1, 4, 8 and 11 
 doxorubicin: 9mg/m2 i.v. on days 1-4 
 dexamethasone: 40mg orally on days 1-4, 9-12 and 17-20 
2. ASCT 
 mobilization of peripheral blood stem cells: 1000mg/m2 cyclophosphamide
on day 1; 15mg/m2 doxorubicin on days 1-4, 40mg dexamethasone orally on 
days 1-4, and G-CSF (10μg/kg filgrastim or 300μg/m2 lenograstim) per day 
subcutaneously divided into 2 doses per day from day 9 until the last stem 
cell collection 
 after stem cell collection patients were treated with 1 or 2 cycles of 
200mg/m2 high-dose melphalan (HDM) and ASCT followed by mainte-
nance therapy  
3. CONSOLIDATION THERAPY - none 
4. MAINTENANCE THERAPY (Start: 4 weeks after HDM) 
 1.3mg/m2 bortezomib i.v. once every 2 weeks for 2 years (if neutrophils 
≥0.5 x 109/l and platelets >20 x 109/l) 
Treatment 
groups 
Control 
1. INDUCTION THERAPY 
three 4-week cycles of vincristine, doxorubicin and dexamethasone (VAD) 
 vincristine: 0.4mg i.v. on days 1-4 
 doxorubicin: 9mg/m2 i.v. on days 1-4 
 dexamethasone: 40mg orally on days 1-4, 9-12 and 17-20 
2. ASCT 
 mobilization of peripheral blood stem cells: 1000mg/m2 cyclophosphamide 
on day 1; 15mg/m2 doxorubicin on days 1-4, 40mg dexamethasone orally on 
days 1-4, and G-CSF (10μg/kg filgrastim or 300μg/m2 lenograstim) per day 
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subcutaneously divided into 2 doses per day from day 9 until the last stem 
cell collection 
 after stem cell collection patients were treated with 1 (HOVON study 
group) or 2 (GMMG study group) cycles of 200mg/m2 HDM and ASCT fol-
lowed by maintenance therapy  
3. CONSOLIDATION THERAPY - none 
4. MAINTENANCE THERAPY (Start: 4 weeks after HDM) 
 50mg thalidomide daily for 2 years 
Progression-free  
survival 
(primary outcome) 
PFS Defined as the time form random assignment until progression, re-
lapse or death, whichever comes first. 
Complete response CR - Absence of the original monoclonal paraprotein (M-protein) 
in serum and (10 x concentrated) urine by immunofixation, 
maintained for at least 6 weeks 
- <5% plasma cells in a representative bone marrow aspirate or 
otherwise in a bone marrow biopsy. Only in patients with 
non-secretory myeloma, bone marrow investigation must be 
repeated after an interval of 6 weeks to confirm CR 
- No increase in size or number of lytic bone lesions (develop-
ment of compression fractures does not exclude CR) 
- Disappearance of any soft tissue plasmacytoma 
Very good partial  
response 
VGPR - Meeting the criteria for PR but show a 90% reduction of se-
rum M-protein concentration for at least 6 weeks 
Partial response PR - 50% reduction of serum M-protein concentration maintained 
for at least 6 week 
- Reduction in 24hrs urine M-protein either by ≥90% or to 
<200mg, maintained for at least 6 weeks 
- In patients with non-secretory myeloma, ≥50% reduction in 
plasma cells in a representative bone marrow aspirate, or oth-
erwise bone marrow biopsy, maintained for at least 6 weeks 
- 50% reduction in size of soft tissue plasmacytoma 
- No increase in size or number of lytic bone lesions (develop-
ment of compression fractures does not exclude PR)  
Minimal response MR - 25% reduction of serum M-protein concentration maintained 
for at least 6 weeks 
- 50% reduction in 24hrs urine M-protein, maintained for at 
least 6 weeks 
- In patients with non-secretory myeloma, ≥25% reduction in 
plasma cells in a representative bone marrow aspirate, or oth-
erwise bone marrow biopsy, maintained for at least 6 weeks 
- 25% reduction in size of soft tissue plasmacytoma 
- No increase in size or number of lytic bone lesions (develop-
ment of compression fractures does not exclude MR) 
No change NC  - Not meeting the criteria of either minimal response or pro-
gressive disease 
Endpoints and 
definitions 
Progressive disease PD - 25% increase in serum M-protein level, which must also be an 
absolute increase of at least 5g/l and confirmed at least once 
- 25% increase in 24h urine M-protein, which must also be an 
absolute increase of at least 100mg/24hrs and confirmed at 
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least once 
- 25% increase in plasma cells in a representative bone marrow
aspirate or bone marrow biopsy 
- Definite increase in the size of existing bone lesions or soft tis-
sue plasmacytoma 
- Development of new bone lesions or soft tissue plasmacytoma 
(development of compression fractures does not exclude con-
tinued response and may not indicate progression) 
- Development of hypercalcaemia (corrected serum calcium 
>2.80 mmol/l) not attributable to any other cause 
Overall survival OS Defined as the time from registration to death from any cause. Pa-
tients still alive were censored at the date of last contact. 
Results and analysis 
Analysis 
description 
Intention-to-treat analysis (ITT) 
The number of events needed to detect the difference (PFS increase to 50% at three years = 
relative hazard ratio of 0.74 for the experimental arm) with a power of 80% and α=0.049 (two-
sided and adjusted for interim analysis at a significance level of 0.001) is 356 and the required 
number of randomly assigned patients is 800. 
Inclusion  patients with newly diagnosed and confirmed diagnosis 
of MM stage II or III according to the Durie-Salmon crite-
ria 
 age 18 to 65 years inclusive 
 WHO performance status 0-3 (WHO=3 is allowed only 
when caused by MM and not by co-morbid conditions) 
Exclusion  systemic amyloid light chain amyloidosis 
 nonsecretory MM 
 serum bilirubin ≥30 μmol/l or aminotransferases ≥2.5 
times normal level 
 neuropathy grade ≥ 2  
 history of active malignancy during the past 5 years with 
the exception of basal carcinoma of the skin or stage 0 
cervical carcinoma 
 HIV positivity 
Analysis popu-
lation 
Characteristics Intervention (PAD) vs Control (VAD), %  
Median age, years (range): 57 (31 to 65) vs 57 (25 to 65) 
Male sex: 61 vs 60 
WHO performance status 0/1/2/3/unknown: 47/41/8/4/1 vs 
44/42/11/2/1 
ISS stage I/II/III/unknown: 35/36/20/9 vs 35/30/26/9 
M-protein isotype 
IgA/IgG/IgD/LCD: 22/61/1/15 vs 23/57/1/19 
M-protein light chain 
kappa/lambda: 67/33 vs 67/33 
Creatinine, mg/dL 
≤2/>2: 91/9 vs 89/11 
No. of skeletal lesions: 
0/1-2/≥3/unknown: 25/11/62/3 vs 23/10/64/3 
Serum LDH 
≤ULN/≥ULN/unknown: 80/17/3 vs 80/17/3 
Genetic abnormalities 
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del(13q), done/ positive, % of done: 88/41 vs 90/44 
t(4;14), done/ positive, % of done: 64/14 vs 63/13 
del(17p13), done/ positive, % of done: 70/9 vs 76/13 
Treatment group Intervention (PAD) Control (VAD) 
Number of subjects n=413 n=414 
P value 
Median PFS, months 35 28 NR 
5-year OS, % 61 55 NR 
Response after induction, % 
CR 
≥nCR 
≥VGPR 
≥PR 
 
7 
11 
42 
78 
 
2 
5 
14 
54 
 
<0.001 
<0.001 
<0.001 
<0.001 
Response after HDM, % 
CR 
≥nCR 
≥VGPR 
≥PR 
 
21 
31 
62 
88 
 
9 
15 
36 
75 
 
<0.001 
<0.001 
<0.001 
<0.001 
Response overall, % 
CR 
≥nCR 
≥VGPR 
≥PR 
 
36 
49 
76 
90 
 
24 
34 
56 
83 
 
<0.001 
<0.001 
<0.001 
0.002 
Descriptive sta-
tistics and es-
timated vari-
ability 
Response upgrade during main-
tenance, % 
any response upgrade 
<CR  CR 
<nCR  nCR 
<VGPR  VGPR 
<PR  PR 
 
 
23 
12 
6 
5 
0 
 
 
24 
11 
4 
7 
3 
 
 
0.64 
0.73 
0.25 
0.30 
0.008 
Comparison groups (PAD )vs Control (VAD) 
HR 0.75 
95% CI 0.62 to 0.90 
Median PFS adjusted for ISS 
P value  0.002 
HR 0.81 
95% CI 0.63 to 1.05 
Effect estimate 
per comparison 
5-year OS adjusted for ISS 
P value  0.11 
Abbreviations: NR – not reported; HR – hazard ratio; CI – confidence interval 
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Table 4: Summary of adverse events from the first interim analysis 
Study ID: HOVON-65/GMMG-HD4 
Outcome, n (%) Intervention, PAD (n=413) Control, VAD(n=414) 
 PAD induction
(n=410) 
Bortezomib 
maintenance 
(n=229) 
VAD induction 
(n=411) 
Thalidomide main-
tenance 
(n=270) 
Any AE 400 (98) 222 (97) 401 (98) 260 (96) 
Grade ≥3 258 (63)* 110 (48) 220 (54) 123 (46) 
AE classified as SAE 187 (46)* 77 (34)* 148 (36) 61 (23) 
AE leading to discontinua-
tion, dose reduction or delay 
of bortezomib 
112 (27) 81 (359 N/A N/A 
Death from AE 7 (2) 0 (0) 9 (2) 0 (0) 
 
 All 
grades 
Grade 
3-4 
All 
grades 
Grade 
3-4 
All 
grades 
Grade 3-
4 
All 
grades 
Grade 3-
4 
Haematologic toxicities, % 
Anaemia 28 8 27* 1 24 7 15 1 
Neutropenia 4 3 2 0 2 1 4 1 
Thrombocytopenia 39# 10* 37# 4 18 5 19 2 
Infections 56 26 75* 24 49 21 61 18 
Herpes zoster 2 0 2 0 0 0 1 0 
Non-haematologic toxicities, % 
Wasting, fatigue 27 4 20 1 28 4 20 1 
GI symptoms 67** 11** 48 5 59 7 40 4 
Cardiac disorders 27 8 19 3 24 5 13 2 
Thrombosis 6 4 1 1 5 3 1 1 
Peripheral neuropathy 37# 24# 33 5 26 10 53# 8 
NOTE: Bold numbers indicate a statistically significant higher proportion compared with the other arm.  
*p<0.01; #p<0.001; **p<0.05 
 
The HOVON-65/GMMG-HD4 trial enrolled 827 patients (PAD arm: 413 vs 
VAD arm: 414) newly diagnosed with MM to assess efficacy of sustained 
bortezomib (i.e. as 2-year maintenance therapy after HDT with ASCT) 
treatment. Baseline patient and disease characteristics were well balanced. 
Information on genetic abnormalities was not available for all patients, but 
for those who was no difference between the two arms existed. 
Of all enrolled patients, 65% in the VAD and 55% in PAD group received 
maintenance treatment with thalidomide and bortezomib, respectively. In 
the VAD arm, 347 patients received HDM. Of these, 77 (22%) patients went 
off protocol after HDM because of alloSCT (n=21; 6%), persisting toxicity 
(n=11; 3%), or other reasons (n=45; 13%). In the PAD arm 229 received 
HDM, of whom 123 (35%) patients went off protocol because of alloSCT 
bortezomib as induction 
before and maintenance 
therapy after ASCT 
VAD vs PAD: 65% vs 
55% of patients received 
maintenance therapy 
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(n=28; 8%), persisting toxicity (n=47; 13%, mainly polyneuropathy) or 
other reasons (n=48; 14%). According to the treatment protocol, mainte-
nance therapy should have been given for 2 years. 47% of patients starting 
bortezomib maintenance and 27% of patients starting thalidomide mainte-
nance therapy actually completed maintenance therapy according to proto-
col. 
Response rates were superior in the PAD arm compared to the VAD arm af-
ter both, induction treatment and high-dose therapy with ASCT. The up-
grade of response during maintenance therapy (i.e. from less than CR to 
CR) was observed to an equal extent in both groups with 23% in the PAD 
arm compared to 24% in the VAD arm. The median time to any response 
upgrade after the start of maintenance therapy was 7 (range 1 to 57) months 
and 6 (range 1 to 35) months in the PAD and VAD group, respectively. 
Median PFS was 7 months longer in the PAD arm compared to the VAD 
arm (HR 0.75; 95% CI 0.62 to 0.90; p=0.002). Median OS was not reached at 
66 months; 5-year OS observed was 61% in the PAD arm and 55% in the 
VAD arm.  
Neben et al. (2012) presented details about the data of the 35 German sites 
which included comprehensive FISH cytogenetic analysis [21]. According to 
this analysis, patients with del(17p13) had improved clinical outcomes when 
treated with PAD compared to VAD. Since del(17p13) was an independent 
predictor for worse PFS and OS outcomes in the control arm, but not in the  
bortezomib arm, this finding suggests, that bortezomib treatment can im-
prove, but not fully overcome adverse outcomes associated with del(17p13) 
[21]. PAD also yielded better, yet not statistically significant results than 
VAD in patients with t(4;14). Further, bortezomib induction and mainte-
nance resulted in superior outcomes in patients with increased serum 
creatinine but not in patients with normal serum creatinine. 
6.2 Efficacy and safety - further studies 
No controlled phase II studies investigating the efficacy and safety of borte-
zomib as consolidation or maintenance therapy after ASCT were found.  
 
superior overall 
response rates in the 
PAD arm 
response upgrade during 
maintenance therapy 
did not differ between 
groups 
+7 months median PFS 
in PAD vs VAD 
bortezomib might 
overcome the adverse 
effect of del(17p13), 
t(4;14) and increased 
serum creatinine 
no controlled phase II 
studies found 
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7 Estimated costs 
Velcade® (bortezomib) is approved as an i.v. injection at a dose of 1.3mg/m² 
body surface area [5]. 
Assuming an average body surface area of 1.79m² [26] 2.33mg of bortezomib 
would be required for one injection. In Austria, one vial of 3.5mg borte-
zomib costs EUR 1,242 [27]. Thus one vial of 3.5mg (EUR 1,242) would be re-
quired.  
Bortezomib as maintenance therapy was administered at a dose of 1.3mg/m² 
once every 2 weeks for the duration of 2 years in the HOVON-65/GMMG-
HD4 trial [21]. For an average patient one two-week cycle is EUR 1,242 re-
sulting in EUR 2,484 per month. Assuming a two-year period maintenance 
therapy with bortezomib results in treatment costs of EUR 59,616.  
A phase III trial investigated bortezomib as consolidation therapy after 
ASCT at a dose of 1.3mg/m² on days 1, 8, 15 and 22 of a five-week cycle (two 
cycles were given) together with thalidomide and dexamethasone. Treat-
ment costs for bortezomib in a consolidation combination would be EUR 
4,968 for one cycle and EUR 9,936 for 2 cycles.  
As bortezomib does not replace any other treatment and is not intended to 
be used as a single-agent in the transplant setting, these cost estimates have 
to be regarded as add-on costs rather than absolute treatment costs. 
8 Ongoing research 
On www.clinicaltrials.gov five ongoing phase III studies investigating the ef-
ficacy and safety of bortezomib included in the consolidation or mainte-
nance treatment after ASCT in newly diagnosed MM patients were found:  
NCT01208766: a phase III trial comparing the efficacy and safety of borte-
zomib, melphalan and prednisone (VMP) with high-dose melphalan fol-
lowed by bortezomib, lenalidomide and dexamethasone (VRD) consolida-
tion and leanlidomide maintenance in newly diagnosed MM patients. The 
estimated completion date for this study is December 2015. 
NCT00416208: this phase III trial investigates the progression free survival 
of patients with MM aged between 61 to 75 years receiving consolidation 
therapy with bortezomib to those without receiving bortezomib after HDT 
with ASCT. Study ends when the last patient will finish the 30-months fol-
low-up; this is estimated to be May 2013. 
NCT00416273: this phase III trial investigates the efficacy and safety of con-
solidation therapy with or without bortezomib after HDT with melphalan 
and ASCT in patients aged between 18 to 60 years. This study will end when 
the last patient has had a follow-up phase of 30 months, which is estimated 
to be May 2013. 
NCT01134484: a randomized phase III study to assess the efficacy and safety 
of bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-
dexamethasone (TD) as induction therapy in preparation for, and as con-
maintenance therapy – 
estimated monthly 
costs: € 2,484.- 
costs for 2-year 
maintenance: € 59,616 
consolidation therapy – 
estimated monthly 
costs: € 4,968.- 
add-on to existing costs 
5 ongoing phase III 
studies found 
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solidation therapy after, melphalan-based double-ASCT in previously un-
treated symptomatic MM patients aged ≤65 years. This study is estimated 
to be completed by December 2015. 
NCT01109004: a phase III study designed to investigate tandem-ASCT plus 
maintenance therapy versus single-ASCT plus consolidation therapy with 
lenalidomide, bortezomib and dexamethasone followed by maintenance 
therapy or single-ASCT plus maintenance therapy as part of upfront treat-
ment of MM. Lenalidomide will be used as maintenance treatment for three 
years in all arms. The primary completion date for this study is estimated to 
be May 2016. 
On www.clinicaltrialsregister.eu four ongoing phase III studies investigating 
bortezomib in the above mentioned indication were found, however, only 
one further trial was identified in addition to those registered at clinical-
trial.gov: 
EudraCT Number 2004-000944-26: this randomized phase III trial aims to 
assess the efficacy of bortezomib combined with intensive chemotherapy and 
as maintenance therapy in comparison with intensive therapy with vincris-
tine followed by thalidomide maintenance in patients with previously un-
treated MM patients. 
9 Commentary  
Bortezomib has been approved by the US FDA and the EMA, as third-line 
therapy in patients with MM who have undergone or cannot undergo ASCT 
since 2003 and 2004, respectively [3, 7]. In 2008, the EMA extended the ap-
proved indication of bortezomib to first-line therapy of patients ineligible 
for ASCT and the US FDA amended the licensed indication to the treat-
ment of MM without further specification. Thus, bortezomib is implicitly li-
censed for consolidation and maintenance therapy in the US but not in 
Europe. In addition, the US FDA approved bortezomib for the treatment of 
patients with mantle cell lymphoma in 2006 [8, 9].  
Up to now, high-dose therapy (HDT) supported by ASCT is considered 
standard of care for first-line therapy in patients with symptomatic MM. 
Within previous years, novel agents such as thalidomide, lenalidomide and 
bortezomib have been investigated and implemented in several treatment 
lines of MM. Recently, these drugs have been incorporated in the front-line 
induction therapy in combination with other agents in clinical treatment 
guidelines [4, 28]. The focus within this HSO report lies on the treatment ef-
fect of bortezomib when used as consolidation or maintenance therapy after 
HDT with ASCT, which is currently in clinical investigation [29]. 
Overall, 2 phase III studies investigating the effect of bortezomib as short-
term consolidation [20] or as 2-year maintenance therapy [22] were in-
cluded. The first study assessed bortezomib with thalidomide and dexa-
methasone as induction and consolidation therapy after HDT with ASCT 
compared to thalidomide and dexamethasone as induction and consolida-
tion therapy. Besides improved response rates compared to the control arm, 
median time to CR or nCR (HR 0.61, 95% CI 0.49 to 0.76; p<0.0001) as well 
as median PFS (HR 0.63, 95% CI 0.45 to 0.88; p=0.0061) were superior in 
since 2003 and 2004 
approved by EMA and 
FDA for the treatment 
of MM 
current standard of 
first-line therapy in 
MM: 
HDT supported by ASCT 
focus of this report: 
bortezomib as 
consolidation or 
maintenance therapy 
improved response rates 
with bortezomib 
combination regimens 
shown in 2 phase III 
trials 
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the intervention arm. AEs reported in detail were only those occurring dur-
ing induction therapy. During or after consolidation therapy 12 (5.1%) pa-
tients in the intervention and 5 (2.1%) patients in the control arm discon-
tinued therapy.  
The second study, the HOVON-65/GMMG-HD4 trial randomised 833 newly 
diagnosed MM patients either to PAD induction and maintenance therapy 
or to VAD induction and maintenance therapy. The objective was to assess 
whether PAD (bortezomib, doxorubicin, dexamethasone) as induction be-
fore HDM with ASCT and as maintenance after HDM with ASCT would 
achieve better response, quality of response, PFS and OS compared to indu-
cation and maintenance with VAD (vincristine, doxorubicin, dexa-
methasone). Response after induction therapy and also response overall was 
better in the PAD arm compared to the VAD arm. Though, response up-
grade during maintenance therapy did not differ between those two groups 
and less patients (55%; n=229) in the PAD arm compared to the VAD arm 
(65%; n=270) received maintenance treatment. 
Neither of the phase III trials reported quality of life (QoL). The most com-
mon and severe adverse events reported were peripheral neuropathy, skin 
rash and gastrointestinal events overall. During maintenance treatment 
anaemia, thrombocytopenia and infections were more frequent in the borte-
zomib-containing arm but peripheral neuropathy of any grade was more fre-
quent in the control arm. AEs specifically reported during bortezomib con-
solidation therapy are not available. 
Even though the studies have used bortezomib as consolidation or as main-
tenance therapy, their role for the treatment of MM remains unclear. By rea-
sons that patients were randomised already to different induction regimens 
and due to missing efficacy results specifically for the maintenance and con-
solidation treatment, the observed effect is mainly attributable to induction 
therapy. To establish if consolidation and/or maintenance therapy offer an 
additional benefit, controlled trials randomising patients to bortezomib or to 
e.g. BSC after HDT+ASCT are needed. 
With the introduction of novel agents (e.g. thalidomide, lenalidomide and 
bortezomib) being used in various treatment lines of MM treatment out-
comes have improved, but concurrently questions regarding the most appro-
priate choice of therapy have arisen. For example, it is unclear which com-
bination regimen should be given as induction therapy; what is the clear ad-
vantage of consolidation or maintenance therapy after ASCT and which 
chemotherapeutic agents should be used in which sequence, combination or 
patients. Another question concerns the optimal timing of HDM with ASCT 
– should it still be administered as upfront therapy or does ASCT yield bet-
ter results as salvage therapy. In the absence of randomised studies compar-
ing the different options head-to-head, it is difficult to recommend a specific 
sequence of regimens. 
Another challenge will be the identification of certain predictive factors (e.g. 
del(17p13) or t(4;14), increased serum creatinine) for selecting patients most 
likely to benefit from bortezomib treatment [20, 22]. 
In addition to the efficacy aspects also safety aspects (e.g. cumulative toxic-
ity with multiple-drug combinations or extended use (e.g. consolidation 
and/or maintenance therapy) of anti-cancer agents) and costs of the different 
treatment regimens have to be considered in the treatment management of 
MM patients.  
response upgrade during 
maintenance therapy 
did not differ between 
treatment groups 
no information on QoL 
available 
the effect of bortezomib 
could not be 
independently assessed 
in the post-transplant 
setting 
while having more 
effective treatment 
options available with 
the novel agents, 
questions about the 
most appropriate 
combination and 
sequence of the 
available options arise 
bortezomib might 
overcome the adverse 
effect of del(17p13) 
not only efficacy but 
also safety issues and 
costs have to be 
considered in the choice 
of therapy 
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To sum up, there are currently multiple effective therapeutic options for the 
treatment of the still incurable disease MM available. In the near future the 
main task will be to find the most effective sequence and combination of 
these therapeutic strategies [15, 30] in order to prolong OS and to improve 
or at least maintain quality of life. 
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